1. [DOXYCYCLINE (UNIDOX SOLUTAB®) AND/OR JOSAMYCIN (WILPRAFEN®) IN TREATMENT OF PATIENTS WITH PROSTATITIS IN REAL CLINICAL PRACTICE. RESULTS OF THE TAURUS OBSERVATIONAL PROGRAM].
- Author
-
Vinarov AZ, Stojlov SV, Kozyrev SV, Surikov VN, Chaban AV, Kurbatov DG, Shpilenja ES, and Nejmark AI
- Subjects
- Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Doxycycline administration & dosage, Doxycycline adverse effects, Drug Therapy, Combination, Humans, Josamycin administration & dosage, Josamycin adverse effects, Male, Prospective Studies, Prostatitis microbiology, Prostatitis psychology, Quality of Life, Surveys and Questionnaires, Anti-Bacterial Agents therapeutic use, Doxycycline therapeutic use, Josamycin therapeutic use, Prostatitis drug therapy
- Abstract
Treatment of chronic prostatitis is a vital and complicated problem, in which a large number of stamps and "stereotyped" approaches often result in uncured patients. The increasing use of intracellular microorganisms in prostatitis etiology requires a modification in the standard approaches. TAURUS study shows high efficacy of doxycycline (Unidox Solutab®) and/or josamycin (Wilprafen®) in chronic prostatitis. Therapy, studied in this program, according to physicians, was effective in 93.2% of patients. Treatment failure was observed in 1.3% of all patients, another 5.5% of patients had insufficient data for assessment. Low incidence of adverse reactions was observed. In the study population, adverse reactions occurred in 2.6% of patients, of them serious adverse events were registered in 0.7% of patients. The most common adverse event in all treatment groups was diarrhea.
- Published
- 2015